Drug Discovery & DDS– category –
-
From Silicon to Synapse: AI Giants Target Pharma, Yet Clinical Timelines Threaten Capital Returns
36Kr China Overview Major AI players, including Anthropic, OpenAI, and Google's Isomorphic Labs, are rapidly entering the life sciences, leveraging AI to accelerate early drug discovery. However, the inherently long timelines for clinica... -
Lonza Offers Integrated ADC Clinical and Commercial Manufacturing Services, Covering Antibody to Sterile Fill-Finish
Lonza Switzerland Overview Lonza offers integrated development and manufacturing services for Antibody-Drug Conjugates (ADCs), encompassing antibodies, payloads, bioconjugation, and sterile fill and finish. The company operates GMP produ... -
CoCoGraph: AI System Unleashes Millions of Novel Molecules, Reshaping Drug Discovery and Materials Science
The Daily Guardian Spain Overview Spanish researchers have introduced CoCoGraph, an AI system powered by graph neural networks that can generate millions of novel, chemically valid molecules. Published in *Nature Machine Intelligence*, t... -
RNAi Therapeutics Advance in Metabolic Disease Treatment with Liver-Targeted DDS and Emerging Self-Delivery siRNAs
ResearchGate (Trends in Pharmacological Sciences) Unknown Overview This article discusses RNA interference (RNAi) as a therapeutic strategy for metabolic diseases, emphasizing its advantage in targeting virtually all genes. Despite deliv... -
NIH’s NCATS Secures FDA IND Clearance for Gene Therapy Targeting Ultra-Rare Multiple Sulfatase Deficiency
National Center for Advancing Translational Sciences - NIH USA Overview The National Center for Advancing Translational Sciences (NCATS), part of the NIH, announced FDA clearance of an Investigational New Drug (IND) application for a gen... -
Pfizer Discontinues Seagen-Developed Solid Tumor ADC Program SGN-MesoC2, Highlighting Persistent ADC Development Challenges
BioSpace USA Overview Pfizer has discontinued another Seagen-developed antibody-drug conjugate (ADC) program for solid tumors, SGN-MesoC2, just weeks after another Seagen-acquired ADC failed a Phase 3 lung cancer study. This cessation un... -
Antibody-Drug Conjugates Show Significant Clinical Activity and Promise in Biliary Tract Cancers
CCA News Online USA Overview Antibody-drug conjugates (ADCs) are emerging as a significant class of cancer therapeutics for biliary tract cancers (BTCs), offering improved outcomes in difficult-to-treat tumors. Advances in ADC technology... -
ASCO Podcast: Optimizing Frontline ADCs as They Shift to Earlier Cancer Treatment Stages
ASCO Publications USA Overview An ASCO Publications podcast discusses the rapid integration of antibody-drug conjugates (ADCs) into frontline advanced and curative-intent perioperative settings for cancer treatment. Experts emphasize tha... -
FDA Accepts BioMarin’s sNDA for Full Approval of VOXZOGO® (vosoritide) in Children with Achondroplasia; PDUFA Date Set for February 28, 2027
BioMarin USA Overview The FDA has accepted BioMarin's supplemental New Drug Application (sNDA) seeking full approval for VOXZOGO® (vosoritide) in children with achondroplasia, setting a PDUFA target action date of February 28, 2027. This... -
Optimized NAMPT Inhibitors Enable Highly Effective ADCs for Liquid and Solid Tumors, Achieving Complete Regressions in Preclinical Models
ACS Bio & Med Chem Au USA Overview This publication details the development of next-generation NAMPT inhibitors as ADC payloads through physicochemical and metabolic optimization. When conjugated to anti-CD30, anti-HER2, or anti-TROP2 an...
